Bevacizumab in Ovarian Cancer: NCT07472140 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2/3
Clinical phase
Recruiting
Recruitment status
120
Planned enrollment
2033-06-30
Primary-completion proxy
Executive view
NCT07472140 evaluates Bevacizumab in Ovarian Cancer. The disclosed sponsor is Sponsor not reported, the design is Interventional, and the geographic footprint is Belarus. The first listed primary endpoint is Disease-free survival, assessed over From enrollment through study completion, an average of 2 year.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07472140 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Ovarian Cancer landscape. Drug & Asset MCP drug_fetch was queried for Bevacizumab, while Company & Deal Intelligence MCP organization_fetch was queried for Sponsor not reported.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07472140 | Bevacizumab | Phase 2/3 / Recruiting | Sponsor not reported | Belarus | Disease-free survival From enrollment through study completion, an average of 2 year | 2033-06-30 |
| NCT07532148 | D-215 | Phase 1 / Not yet recruiting | Chong Kun Dang Pharmaceutical Corp. | Geography not reported | AUCtau 0~12 hours | 2027-06-01 |
| NCT07495397 | Daphnetin | Not Applicable / Recruiting | The First Hospital of Jilin University | China | PFS Every three months. | 2028-06-01 |
| NCT07489287 | GB-5627 | Phase 1 / Recruiting | Roswell Park Comprehensive Cancer Center | United States | Maximum Tolerated Dose (MTD) - Cohort A 28 days from GB-5267 cell infusion | 2028-08-18 |
| NCT07480954 | EB-NK-MF | Phase 1/2 / Recruiting | Beijing Biotech | China | Incidence of dose-limiting toxicities (DLTs) 28 Days | 2027-02-17 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07472140 is a Phase 2/3, recruiting study with 120 planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.
The primary endpoint is “Disease-free survival” over “From enrollment through study completion, an average of 2 year.” The retrieved endpoint description is: Time from randomization to any sign or symptom of the cancer or death from the disease.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 120 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Ovarian Cancer. These records do not establish direct evidence for NCT07472140 unless the registration number matches.
A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Perito…
Phase 3; n=381; Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)(Median) = 5.52 months (95% Confidence Interval, 3.94 - 5.88); Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)(Median): Hazard Ratio (HR) = 0.70(95% CI, 0.54 - 0.91), P-Value = 0.0076 Source: https://clinicaltrials.gov/ct2/show/results/NCT05257408
Dynamic circulating tumor DNA (ctDNA) kinetics refine static HRD profiling to predict PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOC)
Not Applicable; n=145; EMR = 68.0 % Source: https://cslide.ctimeetingtech.com/map2026/attendee/confcal/presentation?q=26P
A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer Wit…
Phase 1; n=12; Rate of Dose Limiting Toxicity (DLT) = 1 Participants ; Rate of Dose Limiting Toxicity (DLT) = 2 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04315233
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Bevacizumab is indexed as Monoclonal antibody with VEGF-A biology and a global stage of Approved. The asset profile lists Genentech, Inc. as an originator or developer.
No exact Company & Deal Intelligence profile was returned for Sponsor not reported. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Bevacizumab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07472140
Protocol source: https://clinicaltrials.gov/study/NCT07472140
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.
Bevacizumab in Ovarian Cancer is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Disease-free survival and 2033-06-30 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
